Patients in distributive shock appear to have a lower risk for atrial fibrillation when vasopressin is added to catecholamine vasopressors, but its effect on other outcomes are mixed, according to a ...
One in eight patients hospitalized with COVID-19 develop some form of shock, according to the American Heart Association’s COVID-19 Cardiovascular Disease Registry. And regardless of whether the shock ...
The PHOENIX trial is a European, placebo-controlled, Phase III study treating catecholamine-resistant patients in distributive shock with the Nitric Oxide (NO) scavenger Pyridoxalated Haemoglobin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results